Pharma shares in focus; CNX Pharma index gains over 2%

At 03:02 PM, the CNX Pharma index was up 2.3% or 279 points at 13,219 compared to a 0.20% decline in CNX Nifty.

SI Reporter Mumbai
Last Updated : Aug 31 2015 | 3:54 PM IST
Shares of pharmaceutical companies are trading higher on the bourses in an otherwise subdued market, with the National Stock Exchange (NSE) CNX Pharma index up more than 2% in late noon deals.

Ajanta Pharma, Dishman Pharmaceuticals and Chemicals, Divi’s Laboratories, Piramal Enterprises, Strides Arcolab, Divi’s Laboratories, Lupin, Cipla, Dr Reddy’s Laboratories and Sun Pharmaceutical Industries are up 2%-5% each on the NSE.

At 03:02 PM, the CNX Pharma index was up 2.3% or 279 points at 13,219 compared to a 0.20% decline in CNX Nifty.

Strides Arcolab have moved higher by 3% to Rs 1,231 after announcing that it achieved closure of transaction for acquisition of a generic pharmaceutical business in Australia and related assets from Aspen.

The acquired business will be integrated and consolidated with Strides effective September 1, 2015, Strides Arcolab added.

Lupin was up 4% at Rs 1,937 on the BSE. The stock has rallied by 7% in the past three trading sessions, from Rs 1,812, after the drug co0mpany received approval from US health regulator USFDA to market generic Omeprazole delayed-release capsules used to treat ulcer in the American market.

The company has received final approval for its Omeprazole delayed-release capsules (40 mg) from the United States Food and Drugs Administration (USFDA), Lupin Ltd said in a statement.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 31 2015 | 3:26 PM IST

Next Story